Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status

Retatrutide peptide research is where incretin science stopped adding one receptor at a time. Retatrutide (development code LY3437943, Eli Lilly) is a single synthetic peptide engineered to activate three metabolic receptors at once — GIP, GLP-1 and glucagon — and its Phase 2 and Phase 3 trial results are the largest weight-change numbers yet reported for a drug in this class. It is also, as of October 2026, not approved by the FDA, the EMA or any other major regulator. This profile separates what the published retatrutide peptide research actually shows from what the headlines skip: the mechanism, the trial-by-trial evidence, the safety signals, and what a laboratory researcher should verify on a certificate of analysis before working with this compound.

For context on how this class evolved, see our profiles of the single agonist semaglutide and the dual agonist tirzepatide — retatrutide is the deliberate next step from both.

What retatrutide is: identity at a glance

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP sequence backbone, first described by Coskun and colleagues at Eli Lilly in 2018. Two non-standard residues — α-aminoisobutyric acid (Aib) — help protect the molecule from enzymatic breakdown, and a C20 fatty diacid side chain attached at the lysine in position 20 binds reversibly to albumin. That albumin binding is what stretches the half-life to roughly six days in humans, which is why the clinical trials were designed around once-weekly administration. None of that makes the research material in a vial an approved medicine — a distinction this article returns to throughout.

Researchers sourcing a retatrutide research peptide should expect exactly those identifiers on the documentation: the CAS number, the ~4,731 Da molecular weight, and a sequence that accounts for the Aib residues and the fatty-acid side chain. If a COA cannot account for the side chain, it is not describing this molecule.

Retatrutide peptide research: the triple-agonist mechanism

Three receptors, three complementary jobs

Most metabolic peptides studied in this area work through one or two pathways. Retatrutide was designed to engage all three simultaneously:

• GLP-1 receptor (GLP-1R) — glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. This is the pathway shared with semaglutide.
• GIP receptor (GIPR) — glucose-dependent insulinotropic polypeptide signaling, with additional roles in adipose-tissue insulin sensitivity and lipid handling. Retatrutide is in fact most potent at the human GIP receptor in preclinical characterization.
• Glucagon receptor (GCGR) — hepatic glucose output, but also increased energy expenditure and hepatic fat oxidation. This third arm is what separates retatrutide from tirzepatide.

Why add glucagon at all?

Glucagon on its own raises blood glucose, which sounds like the opposite of what a metabolic compound should do. The design hypothesis, supported by the trial data below, is that the GLP-1 and GIP arms control the glucose side while the glucagon arm adds something the other two do not: higher resting energy expenditure and direct pressure on liver fat stores. In other words, the first two receptors mainly reduce energy intake; the third is intended to raise energy output. That is also why the liver-fat substudy (below) matters so much for interpreting this compound — it is the cleanest test of whether the glucagon arm is doing real work.

What the mechanism does not establish

Receptor pharmacology in vitro does not predict long-term human outcomes. Open questions the field itself names include the consequences of years-long glucagon-receptor engagement, the dose-dependent rise in heart rate seen in trials (which peaked around 24 weeks in Phase 2 and then declined), and whether weight is regained after discontinuation — a pattern documented for other incretin therapies. Retatrutide peptide research is promising precisely because the numbers are large; it is unfinished for the same reason.

The Phase 2 evidence

Obesity: Jastreboff et al., New England Journal of Medicine, 2023

The pivotal Phase 2 obesity trial randomized 338 adults with obesity, or overweight with a weight-related condition, to once-weekly retatrutide or placebo for 48 weeks (ClinicalTrials.gov NCT04881760). The least-squares mean weight change at 48 weeks was −8.7% at the lowest studied arm, −17.1% and −22.8% at the intermediate combined arms, and −24.2% at the highest studied arm, versus −2.1% on placebo — and the curves had not clearly plateaued when the trial ended. At that highest arm, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15%. The most common adverse events were gastrointestinal, dose-related, mostly mild to moderate, and partly mitigated by a lower starting dose in the trial design.

Type 2 diabetes: Rosenstock et al., The Lancet, 2023

In 281 adults with type 2 diabetes (mean duration 8.1 years), retatrutide produced dose-dependent HbA1c reductions at 24 weeks, reaching −2.02 percentage points at the highest studied arm, versus −0.01 on placebo and −1.41 on the active comparator, dulaglutide 1.5 mg. Body weight at 36 weeks fell by up to 16.94% at the highest arm, versus 3.00% on placebo and 2.02% on dulaglutide. There were no reports of severe hypoglycemia and no deaths in that trial, and the gastrointestinal adverse-event pattern matched the obesity study.

Liver fat (MASLD): Sanyal et al., Nature Medicine, 2024

The Phase 2a liver substudy enrolled 98 participants from the obesity trial who had metabolic dysfunction-associated steatotic liver disease with at least 10% liver fat by MRI-PDFF. Mean relative liver-fat change at 24 weeks was −42.9%, −57.0%, −81.4% and −82.4% across the ascending arms, versus +0.3% on placebo (all p<0.001). Normal liver fat (below 5%) was reached by 86% of participants at the highest arm at 24 weeks, versus 0% on placebo. Liver-fat reduction tracked closely with changes in body weight, waist circumference and insulin-sensitivity measures. This is an imaging endpoint from a small substudy — not biopsy-proven disease resolution — and the article should be read that way.

Phase 3: the TRIUMPH program and TRIUMPH-4

Lilly’s Phase 3 TRIUMPH program extends the Phase 2 questions into larger registration trials across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease and related conditions.

The first Phase 3 readout, TRIUMPH-4, was announced by Lilly on December 11, 2025. In 445 adults with obesity or overweight and knee osteoarthritis, without diabetes — 84% with a baseline BMI of 35 or higher — both studied doses met all primary and key secondary endpoints at 68 weeks. Weight fell by up to an average of 28.7% (71.2 lb from a 248.5 lb baseline) at the highest dose, and WOMAC osteoarthritis pain scores fell by up to 4.5 points (75.8%), with more than one in eight treated participants reporting they were completely free of knee pain. Systolic blood pressure fell by 14.0 mmHg at the highest dose, alongside improvements in non-HDL cholesterol, triglycerides and hsCRP. Discontinuation patterns were broadly consistent with the incretin class, though Lilly noted some participants stopped because of perceived excessive weight loss.

Additional TRIUMPH readouts followed through 2026, and Lilly has indicated it plans a regulatory submission in 2027. A topline press release is not a peer-reviewed paper, and a planned filing is not an approval — researchers should weight TRIUMPH-4 accordingly until the full datasets are published.

Cross-trial comparisons like this table are context, not head-to-head evidence — populations, durations and estimands differ, and no completed trial has randomized retatrutide directly against tirzepatide or semaglutide.

Regulatory status: read this section carefully

• FDA: Retatrutide is investigational. It has no brand name, no approved label on DailyMed, and no legal prescription channel. It is not an FDA-approved treatment for obesity, diabetes, liver disease or any other condition.
• EMA / other regulators: No central authorization exists in the EU, and no major regulator worldwide has approved it as of October 2026.
• What that means for research material: A vial labeled for research is a laboratory reagent for in vitro and qualified laboratory research only. It is not the Lilly investigational product used in the trials above, it has not been through FDA review, and the trial results in this article describe a different, regulated clinical supply chain. Conflating the two is the single most common error in coverage of this compound — including, recently, in slang-driven social posts that call it “reta” or group it with other “peps” as if it were an approved product. It is not.

Laboratory considerations: verifying retatrutide in the lab

Because demand for this compound runs ahead of its regulatory status, identity verification matters more here than for almost any other peptide in the catalog:

• Mass spectrometry is the identity test. At ~4,731 Da, retatrutide sits in a range where a correct multiply-charged ESI envelope and deconvoluted mass are hard to fake. Our guide to peptide mass spectrometry walks through reading that data.
• HPLC is the purity test. A single main peak by RP-HPLC, with deletion sequences and incomplete side-chain coupling accounted for in the impurity profile, is the minimum to expect. See how to read a COA and our COA & third-party testing overview.
• The Aib residues and C20 side chain are the fingerprint. A generic 39-mer with the right nominal mass but standard residues is a different molecule. Sequence-level documentation should show both modifications explicitly.
• Storage follows the lyophilized-peptide rules in our peptides hub: keep lyophilized material sealed, cold and dry, equilibrate before opening, and treat reconstituted material as short-lived — the fatty-acid side chain does not make the peptide backbone indestructible.

FAQ: questions researchers actually ask

Is retatrutide FDA-approved?

No. It is an investigational Eli Lilly compound in Phase 3 trials. There is no approved brand-name retatrutide product, and research-use-only material is not an approved medicine.

How is retatrutide different from tirzepatide?

Tirzepatide activates two receptors (GIP and GLP-1). Retatrutide adds a third — the glucagon receptor — which is hypothesized to raise energy expenditure and reduce liver fat. Our tirzepatide profile covers the dual-agonist data in full.

What is the strongest evidence for retatrutide?

The peer-reviewed Phase 2 program: −24.2% mean weight change at 48 weeks in obesity (NEJM, 2023), HbA1c −2.02 points in type 2 diabetes (The Lancet, 2023), and −82.4% relative liver-fat reduction at 24 weeks in the MASLD substudy (Nature Medicine, 2024). TRIUMPH-4 adds the first Phase 3 topline (−28.7% at 68 weeks), pending full publication.

Why do the Phase 3 numbers differ between reports?

Because trials report different estimands. An efficacy estimand estimates the effect if treatment is taken as directed; a treatment-regimen estimand includes participants who stopped. Both can be correct while producing different percentages for the same trial — check which one a headline is quoting.

What should a retatrutide COA show?

Identity by mass spectrometry matching ~4,731.33 g/mol, purity by HPLC with the chromatogram shown, the CAS number 2381089-83-2, and documentation of the Aib residues and C20 fatty diacid side chain.

Related in the Apex shop: Retatrutide research peptide — supplied strictly for laboratory research use.

Disclaimer: This article is for laboratory research education only. All products discussed are supplied strictly for in vitro and laboratory research use only (RUO). Nothing here is medical advice, a dosing recommendation, or a claim of safety or efficacy for human use. Retatrutide is an investigational compound that is not approved by the FDA or any other major regulator.